CYPHERTM Stent Post-Marketing Surveillance Registry (US-PMS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00245401|
Recruitment Status : Completed
First Posted : October 28, 2005
Last Update Posted : April 4, 2007
|Condition or disease||Intervention/treatment||Phase|
|Coronary Artery Disease||Device: CYPHERTM Sirolimus-Eluting Coronary Stent||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||2070 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||CYPHERTM Stent Post-Marketing Surveillance Registry (US-PMS)|
|Study Start Date :||August 2003|
|Actual Study Completion Date :||December 2004|
- MACE at 30 days, 6 months and 1 year.
- There is no pre-specified secondary outcome.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00245401
|Principal Investigator:||Emerson Perin, MD||Texas Heart Institute|